论文部分内容阅读
目的观察干扰素a-2b肝肿瘤局部注射联合肝动脉灌注化疗+栓塞(tramscatheter hepaticarterid chemoemblization TACE)治疗中晚期肝癌的临床疗效。方法观察组68例,经皮“B”超定位下,肝肿瘤内注射干扰素a-2b后联合TACE术;对照组82例,单纯用TACE,比较两组方法的疗效。结果观察组、对照组有效率分别为67.6%和51.3%,观察瘤体缩小两组差异有显著性(P<0.05),观察组生存质量明显提高,Kamofskg评分差异有显著性(P<0.05)。结论干扰素局部注射联合TACE来治疗原发性肝癌,增强了抗癌效果,改善了患者的生存质量。
Objective To observe the clinical efficacy of local injection of interferon a-2b liver tumor combined with hepatic arterial chemoembolization (TACE) in the treatment of advanced hepatocellular carcinoma. Methods Twenty-eight patients in the observation group underwent percutaneous injection of interferon a-2b after percutaneous “B” superpositioning and TACE. 82 patients in the control group were treated with TACE alone. The efficacy of the two groups was compared. Results The effective rates of observation group and control group were 67.6% and 51.3%, respectively. The difference between the two groups was statistically significant (P<0.05). The quality of life in the observation group was significantly improved, and the Kamofskg score was significantly different (P<0.05). . Conclusion Local injection of interferon combined with TACE to treat primary liver cancer enhances the anti-cancer effect and improves the patient’s quality of life.